GLOBAL HEALTH | GLOBAL PARTNERSHIPS | GLOBAL IMPACT

Research

Photo for VELETI II

VELETI II

Official Title

Sealing Moderate Coronary Saphenous VEin Graft Lesions with Paclitaxel-Eluting Stents and/or PROMUS Element TMstent as a New Approach to MainTainingVeIn Graft Patency and Reducing Cardiac Events

Status

Ongoing

Overview

To evaluate the efficacy of stenting moderate SVG lesions with paclitaxel-eluting stents and/or PROMUS Element stent on reducing the first occurrence of the composite of cardiac death, myocardial infarction or repeat revascularization related to the target SVG over the duration of follow-up

Study Design

Randomized, prospective, multicenter study assessing the efficacy of stenting moderate saphenous vein graft (SVG) lesions with paclitaxel eluting stents and/or PROMUS Element stent in the prevention of SVG atherosclerosis progression and cardiac events follow-up.

Primary Endpoint

The first occurrence of the composite of cardiac death, myocardial infarction related to the target SVG or coronary revascularization related to the target SVG over the duration of the follow-up.

Number of Patients

125

Number of Sites

20

Number of Countries

1

Study Period

2011–TBA

Principal Investigator

Josep Rodes Cabau

Program Manager

Susan Chrolavicius, Brandi Meeks

Research Coordinator

Barbara Jedrzejowski, Brandi Meeks

Collaborators

CANNeCTIN/CIHR/Boston Scientific